RegulatoryCompany release

FDA extends review of Belite Bio's tinlarebant for Stargardt disease to May 2027

Belite Bio, Inc (BLTE) · Fri 20 Nov 2026

The US regulator has pushed the action date for Belite Bio's Stargardt disease type 1 application back by three months, saying it needs more time to review supporting information.

Belite Bio announced on 20 November 2026 that the US Food and Drug Administration has extended the review of its new drug application for tinlarebant in Stargardt disease type 1. The Prescription Drug User Fee Act (PDUFA) action date moves back by three months to 12 May 2027.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Belite Bio, Inc ↗

Article written by VigiEye from the official source (Belite Bio, Inc). Claims are the company's own. AI-assisted; check the source before acting.